Neurocrine Biosciences, Inc.
NBIX
$151.39
-$1.09-0.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.61% | 18.42% | 21.73% | 24.81% | 25.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.61% | 18.42% | 21.73% | 24.81% | 25.72% |
| Cost of Revenue | 37.80% | 38.90% | 39.61% | 26.53% | 22.55% |
| Gross Profit | 11.08% | 9.02% | 13.52% | 24.00% | 27.27% |
| SG&A Expenses | 23.22% | 21.00% | 18.76% | 15.05% | 10.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.53% | 28.58% | 27.36% | 19.70% | 15.22% |
| Operating Income | -8.28% | -10.94% | 3.61% | 44.12% | 69.10% |
| Income Before Tax | 20.51% | 17.95% | -0.79% | 46.34% | 107.15% |
| Income Tax Expenses | 47.83% | 66.02% | 60.08% | 75.61% | 123.19% |
| Earnings from Continuing Operations | 10.91% | 2.68% | -17.28% | 36.68% | 102.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.91% | 2.68% | -17.28% | 36.68% | 102.04% |
| EBIT | -8.28% | -10.94% | 3.61% | 44.12% | 69.10% |
| EBITDA | -7.28% | -9.80% | 4.67% | 43.26% | 66.89% |
| EPS Basic | 11.36% | 1.47% | -19.25% | 33.68% | 96.91% |
| Normalized Basic EPS | -6.68% | -8.81% | 5.34% | 43.71% | 68.81% |
| EPS Diluted | 11.91% | 1.96% | -18.85% | 35.69% | 101.13% |
| Normalized Diluted EPS | -6.03% | -8.11% | 5.82% | 43.60% | 68.38% |
| Average Basic Shares Outstanding | -0.50% | 0.73% | 2.01% | 2.74% | 2.88% |
| Average Diluted Shares Outstanding | -1.26% | -0.05% | 1.57% | 3.49% | 3.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |